Influenza vaccine strains: Recombinant antigens from 2015–2024

Seasonal flu, a common infectious disease of the respiratory tract, is caused by the influenza virus. There are four kinds of influenza virus, influenza type A, B, C, and D.

As far as the medical community is concerned, the A and B types are of great interest because they can cause seasonal epidemics. Influenza A, such as the A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2), could even result in global pandemics.

To avoid flu infection, vaccination is the most efficient method. On an annual basis, different flu strains are chosen as vaccine candidates depending on surveillance data of the new isolates and the vaccines’ performance from the earlier season.

In recent years, most influenza vaccines have been quadrivalent or trivalent, made of one H1N1, one H3N2, and either one or two type B viruses (Victoria lineage and Yamagata).

Image Credit: Sino Biological Inc

Sino Biological provides recombinant flu antigen products under its ProVir^® viral antigen collection. The product line spans Neuraminidase (NA), Hemagglutinin (HA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in the past few years.

Such antigens could be utilized to examine vaccine-induced antibody response. Sino Biological also has many monoclonal antibodies against the flu antigens. Such reagents could help streamline appropriate assay development.

Year 2023–2024

Table 1. Source: Sino Biological Inc

Year 2022–2023

Table 2. Source: Sino Biological Inc

Year 2021–2022

Table 3. Source: Sino Biological Inc

Year 2020–2021

Table 4. Source: Sino Biological Inc

Year 2019–2020

Table 5. Source: Sino Biological Inc

Year 2018–2019

Table 6. Source: Sino Biological Inc

Year 2017–2018

Table 7. Source: Sino Biological Inc

Year 2016–2017

Table 8. Source: Sino Biological Inc

Year 2015–2016

Table 9. Source: Sino Biological Inc